Iruzid 10 mg/12,5 mg tablete
| Name | Iruzid 10 mg/12,5 mg tablete |
|---|---|
| Marketing Authorisation Number | HR-H-169873914 |
| Active Substance | lizinopril dihidrat hidroklorotiazid |
| Composition | jedna tableta sadrži 10 mg lizinoprila u obliku lizinopril dihidrata i 12,5 mg hidroklorotiazida |
| Pharmaceutical Form | tableta |
| Packaging [MA Number for Packaging] | 30 tableta u blisteru, u kutiji [HR-H-169873914-01] 60 tableta u blisteru, u kutiji [HR-H-169873914-02] |
| Manufacturer | Belupo lijekovi i kozmetika d.d., Koprivnica, Hrvatska |
| Marketing Authorisation Holder | Belupo lijekovi i kozmetika d.d., Ulica Danica 5, Koprivnica, Hrvatska |
| Marketing Authorisation Date | 22.12.2016 |
| MA Period of Validity | unlimited |
| Classification Number | UP/I-530-09/16-02/72 |
| Registration Number | 381-12-01/30-16-05 |
| Prescription | na recept |
| Type of prescription | ponovljivi recept |
| Distribution | u ljekarni |
| Advertising to general public | zabranjeno |
| ATC Code | C09BA03 |
| Medicinal product marketed in the Croatia | Da |
| SmPC | download |
| PL | download |
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o riziku od nemelanomskog raka kože povezanog s primjenom hidroklorotiazida | 17.10.2018 | Alkaloid, Belupo, Berlin-Chemie Menarini, Boehringer Ingelheim International, Farmal, Genericon, Pharma, Jadran Galenski laboratorij, Krka - farma, Merck, Merck Sharp & Dohme, Novartis, PharmaSwiss, Pliva, Sandoz, sanofi-aventis i Stada |
